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Abstract The objective was to
identify the sociodemographic
and clinical characteristics of a
large sample of patients with
migraine in Mexico City. This
cross-sectional study was per-
formed in two tertiary centers in
Mexico City and affiliated
hospitals. We evaluated the
presence of migraine through a
standardised interview according
to the criteria of the International
Headache Society. We studied
1147 patients. The mean age was
37.1±13.6 (6–77) years. Nine
hundred and twenty one patients
were female (80%). The age of
onset of migraine was 19.4±10.3
(1–69) years. Six hundred and
four patients had migraine with
aura (53%) and 543 without aura
(47%). The female/male ratio was
4:1. One hundred and forty-seven
patients had cardiovascular
problems (13%), 72 had
neurological problems (6%),
233 had gastrointestinal
problems (20%) and 323 had
psychiatric problems (28%).
In this study we described the
clinical characteristics of a large
sample of patients with migraine
in Mexico City. Our sample has
similar characteristics to other
countries.
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Introduction
Epidemiology has several important implications for the
diagnosis and treatment of migraine. Migraine’s preva-
lence and distribution in different countries and its
impact on individuals and on societies needs to be
addressed. Examination of sociodemographic, familial
and environmental risk factors helps to identify the
groups at highest risk for headache and may ultimately
provide clues to preventive strategies or mechanisms of
the disease [1]. At the present time clinical studies of
migraine are more reliable because they use the criteria of
the International Headache Society (IHS), which are
more complete, explicit and rigorous than the criteria that
were used in previous studies [2–4].
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Migraine prevalence varies by age and gender. Before
puberty, migraine prevalence is higher in boys than in
girls; then the prevalence increases more rapidly in girls
than in boys as adolescence approaches [5, 6]. Prevalence
increases until approximately age 40, when it declines [7,
8]. The gender ratio also changes with age. Cyclical hor-
monal changes associated with menses may account for
some aspects of the migraine prevalence ratio. However,
hormonal factors cannot account for all of the gender dif-
ferences; prevalence remains substantially higher in
women than men, even at 70 years of age, well beyond the
time that cyclical hormonal changes may be considered a
predisposing factor [9].
Migraine is comorbid with a number of neurological
and psychiatric disorders. Understanding the comorbidity
of migraine is potentially important from a number of dif-
ferent perspectives. First the occurrence of comorbidity
has implications for the diagnosis of headache because
migraine has a substantially symptomatic overlap with
several of the comorbid conditions, for example migraine
and epilepsy can cause transient alterations of conscious-
ness as well as headache. Second, comorbidity has impor-
tant implications for treatment. Comorbid conditions may
impose therapeutic limitations, but may also create thera-
peutic opportunities. For example, when migraine and
depression occur together, an antidepressant may success-
fully treat both conditions. Finally the study of comorbid-
ity may provide epidemiological clues to the fundamental
mechanism of migraine [10].
The American Migraine Study [9] found that approxi-
mately 23 million Americans suffered severe migraine;
more than 85% of women and 82% of men with severe
migraine had a headache-related disability. This is a
chronic disorder that usually accompanies the patient
from his diagnosis through the rest of his life.
Epidemiological information in developing countries is
scant and is necessary because risk factors and social atti-
tudes toward migraine can be identified, which may influ-
ence health care. In this study we described the character-
istics of a large population of patients with migraine that
were prospectively included in a genetic study exploring
clinical characteristics and comorbidity.
Materials and methods
This cross-sectional study was performed at the Neurology
Department of the Instituto Nacional de Ciencias Médicas y
Nutrición Salvador Zubirán (INCMNSZ) and the Migraine
Clinic of the National Institute of Neurology. These hospitals are
national reference centres for different neurological diseases in
Mexico. The study was approved by the local Institutional
Review Board of the two institutions. The data collection was
performed between March 2003 and July 2004. Patients with
known secondary causes of headache and patients who declined
the interview and the clinical examination were not included.
Patients were approached for consent to participate in our study
in a consecutive manner. Through a standardised interview
according to the criteria of the IHS and a physical examination
performed by a physician, we evaluated the presence of
migraine. The headache test uses 49 questions and classifies
headache into migraine with aura (MA), migraine without aura
and tension headache; it also assesses the type and frequency of
pain medications used for the treatment of headache. For this
study we only used the migraine section. It has been previously
tested in a healthy Mexican population [11–13]. This question-
naire measures some sociodemographic data and disability. All
previous or present disease manifestations were recorded from
patient’s clinical files and with a clinical interview. A blood sam-
ple was taken from all patients to perform a genetic analysis
(these results will be available at the end of 2005). We used the
MIDAS questionnaire to evaluate headache-related disability
[14]. The presence of migraine in the last year was ascertained
according to the validated questionnaire [11]. The percentage of
patients who refused to participate was 5%.
Statistical analysis
A descriptive analysis was used in accordance with the level of
measurement of the variables. Patients were grouped according to
the presence or absence of aura, to compare several sociodemo-
graphic, clinical and morbidity characteristics. Mann-Whitney or t-
test and Chi-square tests were performed to evaluate associations
with quantitative and categorical variables respectively; the signif-
icance was adjusted at p<0.05. To compare the frequency of
migraine in the different age groups we calculated the risk ratio




We studied 1147 patients. Mean age was 37.1±13.6 years
(6–77). Nine hundred and twenty-one patients were
female (80%) and 226 male (20%). The age onset of
migraine was 19.4±10.3 years (1–69). The majority of
patients had nausea during the episodes of headache
(88%), phonophobia (80%) and photophobia (92%). In
the analysis by gender, males had an early onset of
migraine, higher height and weight and higher frequency
of alcoholism and smoking habit. Six hundred and four
patients had MA (53%). The rest of the characteristics are
shown in Table 1.
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Disability and comorbidity
The migraine disability scale showed 341 patients in grade I
and II (30%), 399 in grade III (35%) and 407 in grade IV
(36%). One hundred and forty-seven patients had cardiovas-
cular problems (13%); the most frequent were hypertension in
120 patients (11%). Seventy-two had neurological problems
(6%); the most frequent was benign paroxysmal positional
vertigo (BPPV) in 28 (2%). Two hundred and thirty-three had
gastrointestinal problems (20%), functional bowel disorders
being the most frequent, in 180 (16%). Three hundred and
twenty-three patients had psychiatric problems, with depres-
sion as the most frequent in 212 (18%). Cardiovascular, neu-
rological and psychiatric medical conditions were more fre-
quent in females with migraine (p<0.05) (Tables 2 and 4).
Risk ratio female/male
Table 3 shows the risk ratio (RR) female/male according to
different groups of age and types of migraine. The
Table 1 General description of the cohort
Females (n=921) Males (n=226) p* Total (n=1147)
General characteristics
Age, mean±SD 39.3±13.1 31.3±13.8 0.39 37.1±13.6
Age of onset of migraine, mean±SD 20.1±10.3 16.6±10.9 0.001 19.4±10.3
Height, mean±SD 157.1±168.6 168.6±12.4 0.001 159.4±10.3
Weight, mean±SD 63.1±12.0 71.8±14.7 0.001 64.8±13.7
Body mass index, mean±SD 25.4±4.6 24.8±4.4 0.82 25.3±4.5
Migraine with aura, n (%) 494 (54) 110 (49) 0.20 604 (53)
Smoking, n (%) 184 (20) 73 (32) 0.001 257 (22)
Alcoholism, n (%) 43 (5) 26 (12) 0.001 69 (6)
Accompanying symptoms, n (%)
Nausea 816 (89) 187 (83) 0.01 1012 (88)
Vomiting 572 (62) 130 (58) 0.20 741 (66)
Phonophobia 543 (59) 123 (54) 0.21 921 (80)
Photophobia 480 (52) 110 (49) 0.34 1050 (92)
*Comparison between males and females
Table 2 Disability, comorbidity and triggers
Females, n (%) Males, n (%) p* Total, n (%) 
(n=921) (n=226) (n=1147)
Migraine disability
Grade I and II 264 (29) 77 (34) 0.11 341 (30)
Grade III 326 (35) 73 (32) 0.38 399 (35)
Grade IV 331 (36) 76 (33) 0.51 407 (36)
Comorbidity
Cardiovascular problems 139 (15) 8 (4) 0.001 147 (13)
Neurological problems 62 (7) 10 (4) 0.20 72 (6)
Gastrointestinal problems 214 (23) 19 (8) 0.001 233 (20)
Psychiatric problems 283 (31) 40 (18) 0.001 323 (28)
Triggers
Stress 339 (37) 82 (36) 0.88 421 (36)
Menstruation 108 (12) 0 (0) NC 108 (9)
Food 88 (10) 14 (6) 0.11 102 (9)
Alcohol 60 (7) 16 (7) 0.39 76 (7)
Smoking 49 (5) 12 (5) 0.64 61 (5)
Food 88 (10) 14 (6) 0.28 102 (9)
Stress 339 (37) 82 (36) 0.13 421 (37)
Exercise 25 (3) 17 (8) 0.001 42 (4)
Others 11 (1) 1 (0.4) 0.06 12 (1)
*Comparison between males and females. NC, not calculated
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female/male RR in the whole population was 4.8 (95% CI
3.8–4.3), in patients with migraine without aura was 3.3 (95%
CI 3.0–3.7) and in patients with aura was 4.4 (95 CI 4.1–4.9).
Triggers
The main triggers were stress in 421 patients (36%), men-
struation in 108 (9%), food in 102 (9%) and alcohol in 76
(7%). Exercise as a trigger was most frequent in males
(p<0.05). The other triggers are shown in Table 4.
Comparison between patients with and without aura
We did a comparison between patients with and without
aura. We found differences in the clinical symptoms;
patients with aura had a higher frequency of nausea, vom-
iting, phonophobia and photophobia (p<0.05). The other
characteristics are shown in Table 5.
Discussion
The public health significance of migraine is often over-
looked; probably because of its episodic nature and the
lack of mortality due to the disorder. Migraine is, how-
ever, a frequently incapacitating disorder with consider-
able impact on social activities and work in the people
who suffer it, and may lead to significant consumption
of drugs.
The female preponderance in migraine is consistent
across the different studies; the majority of the studies
show that migraine is more common in females than in
males with a ratio of about 1:2 to 3. Both migraine with
and without aura show female preponderance [4] and the
over-representation of women seems more clear-cut in
migraine without aura [3]. In our study all the groups
showed a preponderance of females, including the gener-
al population and the two groups of migraine analysed in
our study. Interestingly the female/male RR in patients of
less than 15 years is slightly favourable to the males in the
general population of migraineurs and in migraineurs
without aura. Only the patients with aura showed a female
preponderance in this age group (Table 3). This observa-
tion agrees with the previous observations of Bile [15].
They showed that the prevalence of migraine rises from
1% at 6 years of age to 5% at 15 years of age. No sex dif-
ference was apparent until age 11; above that age a female
preponderance appeared.
The most common age of onset of migraine is in the
second and third decade and onset is infrequent after
middle age [16]. The mean age of onset of migraine in
our cohort is in the second decade, in accordance with
the observations in previous studies. Interestingly, the
Table 3 Female/male risk ratio in different groups of age and type of migraine
Females, n (%) Males, n (%) RR (95% CI)
General population
Less than 15 years 22 (2) 29 (13) 0.7 (0.4–1.1)
15–29 years 202 (22) 74 (33) 2.7 (2.3–3.1)
30–45 years 367 (40) 86 (38) 4.2 (3.4–4.7)
45–59 years 272 (30) 31 (14) 8.7 (7.7–9.8)
Over 60 years 58 (6) 6 (3) 9.6 (7.3–12.5)
Overall 921 (100) 226 (100) 4.8 (3.8–4.3)
Migraine without aura
Less than 15 years 9 (2) 21 (17) 0.4 (0.2–0.8)
15–29 years 92 (22) 40 (32) 2.3 (1.8–2.8)
30–45 years 171 (41) 45 (36) 3.8 (3.2–4.4)
45–59 years 118 (28) 16 (13) 7.3 (6.1–8.8)
Over 60 years 29 (7) 2 (2) 14.5 (9.7–20.8)
Overall 419 (100) 124 (100) 3.3 (3.0–3.7)
Migraine with aura
Less than 15 years 13 (3) 8 (7) 1.6 (0.8–2.7)
15–29 years 110 (22) 38 (35) 2.8 (2.3–3.4)
30–45 years 194 (39) 46 (42) 4.2 (3.6–4.8)
45–59 years 151 (31) 14 (13) 10.7 (9.1–12.6)
Over 60 years 26 (5) 4 (4) 6.5 (4.2–9.5)
Overall 494 (100) 110 (100) 4.4 (4.1–4.9)
RR, risk ratio
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age of onset was earlier in males (Table 1). Other
observations such as the larger height and weight of the
Mexican males with migraine are expected observa-
tions according to previous studies in the Mexican pop-
ulation [17].
MA is a primary headache disorder that affects about
30% of migraine sufferers. In some patients MA is associ-
ated with attacks of migraine without aura and this coex-
istence has sparked a debate as to whether these forms of
migraine are actually clinically distinct entities [18]. The
Table 4 Comorbidity of migraine (n=1147)
Disease Females, n (%) Males, n (%) p Total, n (%) 
(n=921) (n=226) (n=1147)
Cardiovascular problems (overall) 139 (15) 9 (4) 0.001 147 (13)
Hypertension 113 (12) 7 (3) 0.06 120 (10)
Raynaud phenomenon 5 (1) 0 (0) 0.56 5 (0.4)
Mitral valve prolapse 3 (0.3) 0 (0) 0.19 3 (0.2)
Ischaemic cardiopathy 7 (1) 0 (0) 0.47 7 (0.6)
Other cardiovascular problems 11 (1) 1 (0.4) 0.11 12 (1)
Neurological problems (overall) 62 (7) 10 (4) 0.20 72 (6)
Epilepsy 15 (2) 3 (1) 0.15 18 (2)
BPPV 25 (3) 3 (1) 0.38 28 (2)
Stroke 1 (0.1) 0 (0) 0.16 1 (0.08)
Other neurological problems 21 (2) 4 (2) 0.14 25 (2.1)
Gastrointestinal problems (overall) 214 (23) 19 (8) 0.001 233 (20)
Functional bowel disorders 164 (18) 16 (7) 0.56 180 (16)
Peptic problems 13 (1) 2 (1) 0.57 15 (1)
Others 37 (4) 1 (0.4) 0.17 38 (3)
Psychiatric problems (overall) 283 (31) 40 (18) 0.001 323 (28)
Depression 191 (21) 21 (9) 0.06 212 (18)
Anxiety disorders 64 (7) 10 (4) 0.73 74 (6)
Other psychiatric problems 28 (3) 9 (4) 0.01 37 (3)
BPPV, benign paroxysmal positional vertigo
Table 5 Comparison between patients with and without aura
Without aura (n=543) With aura (n=604) p
Age, mean±SD 37.3±13.8 37.9±13.3 0.4
Age of onset of migraine, mean±SD 20.0±10.1 18.9±10.9 0.08
Height, mean±SD 158.5±11.8 150.1±8.6 0.08
Weight, mean±SD 64.0±14.1 65.4±13.3 0.33
Body mass index, mean±SD 25.2±4.4 25.4±4.7 0.07
Females, n (%) 494 (91) 419 (69) 0.20
Headache in the family, n (%) 334 (62) 383 (63) 0.85
Migraine disability (Grade IV), n (%) 269 (50) 331 (55) 0.17
Nausea, n (%) 451 (83) 542 (90) 0.01
Vomiting, n (%) 285 (52) 412 (68) 0.00
Phonophobia, n (%) 270 (50) 392 (65) 0.00
Photophobia, n (%) 237 (44) 351 (58) 0.00
Cardiovascular problems, n (%) 67 (12) 78 (13) 0.92
Neurological problems, n (%) 29 (5) 43 (7) 0.27
Gastrointestinal problems, n (%) 101 (19) 131 (22) 0.26
Psychiatric problems, n (%) 141 (26) 177 (29) 0.29
Food, n (%) 35 (6) 66 (11) 0.01
Menstruation, n (%) 181 (33) 238 (39) 0.06
Stress, n (%) 52 (10) 55 (9) 0.76
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IHS diagnostic criteria provide a clinical description of
the aura; aura consists of transient, unilateral or bilateral
visual, sensory or motor symptoms considered to arise
from a recurrent reversible, idiopathic dysfunction of the
cortex or brainstem. One of the most important findings in
our study was the high frequency of MA. In the majority
of studies performed in the general population the fre-
quency varies from 15% to 30%. We consider that this
finding could be explained by a reference bias. Both insti-
tutions are national reference centres for complex neuro-
logical conditions and this could be the reason for the high
prevalence of MA. On the other hand it is worth noting the
high frequency of accompanying symptoms in patients
with aura; this observation could be explained in the same
way as the high frequency of patients with aura. It is pos-
sible that the most complicated patients are referred to
specialised centres in Mexico. This preponderance of
patients with MA with more complications and more
symptoms has been seen in studies of epilepsy clinics and
tertiary centres in other populations [19, 20].
Migraine and epilepsy are comorbid. Andermann
reported a median epilepsy prevalence of 5.9% (range
1%–17%) in migraineurs, which greatly exceeds the pop-
ulation prevalence of 0.5% [21, 22]. Perhaps an altered
brain state increases the risk of both migraine and epilep-
sy and thus accounts for the comorbidity of these disor-
ders [22]. Genetic or environmental risk factors may
increase neuronal excitability or decrease the threshold for
both types of attacks. A reduction in brain magnesium [23]
or alterations in neurotransmitters provide plausible
potential substrates for this increase in neuronal excitabil-
ity [24]. In our study the frequency was 2%, which is in
the range of reported frequencies.
The comorbidity of migraine with psychiatric condi-
tions is well established [25]. As for affective disorders,
the lifetime prevalence of major depression is 34.4% in
patients with migraine and 10.4% in patients without
migraine. The lifetime prevalence of anxiety disorders in
migraine is significantly increased in comparison to con-
trols with panic disorders (10.9% vs. 1.8%), generalised
anxiety disorders (8.6% vs. 1.8%) and phobic disorders
(39.8% vs. 20.6%). In our study the most frequent disor-
ders were depression and anxiety disorders. The main bias
in this observation is the source of the information. As we
comment in methods, we obtained the information from
the clinical charts and a general interview with the
patients. It is possible that if we had done a direct evalua-
tion of psychiatric comorbidity we would have obtained a
higher frequency of these alterations. For this reason the
frequency of depression is lower in our population than
that reported in the literature.
The ascertainment of chronic conditions varies in the
different studies performed in several countries. In our
study we used the information contained in charts and the
information supplied by the patient; this being the main
weakness of our study because we could over- or under-
estimate the prevalence of the different medical condi-
tions. Even so, many researchers have found a good cor-
relation between the different methods of measuring
comorbidity and our method is a widely accepted method-
ology to ascertain many chronic medical conditions
including hypertension, coronary heart disease, cancer,
arthritis and other cardiovascular diseases. On the other
hand the lack of a control group does not permit the esti-
mation of the prevalence of these chronic medical condi-
tions in the general population to perform a comparison
with migraineurs [10, 26, 27].
Many environmental factors and physiologic influ-
ences may provoke a migraine attack or increase its sever-
ity. Menstruation is a common migraine trigger or
enhancer. Changes in body rhythm such as sleep depriva-
tion, too much sleep or fasting may provoke an attack.
Minor head trauma and changes in weather may trigger
migraine. In approximately 15%–20% of patients with
migraine, foods may be a provocative factor; foods that
are related to migraine are chocolate, strong cheeses, cit-
rus fruits and sometimes the sweetener aspartame; they
may all trigger a migraine attack. Excessive use of caf-
feine-containing foods and caffeine withdrawal may trig-
ger both migraine and tension headaches [28]. In our
study the main trigger was stress in 36%, followed by
menstruation and food, which are classically described as
the principal triggers.
In this study we described the clinical characteristics
of a large sample of patients with migraine in Mexico
City. The majority of characteristics of our sample are
similar to other reports, except that in our sample the fre-
quency of MA was higher. This finding could be explained
by a reference bias of the participating institutions, but it
could be explained by genetic and race variations.
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